naltrexone and baclofen

naltrexone has been researched along with baclofen in 53 studies

Research

Studies (53)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (1.89)	18.7374
1990's	3 (5.66)	18.2507
2000's	20 (37.74)	29.6817
2010's	23 (43.40)	24.3611
2020's	6 (11.32)	2.80

Authors

Authors	Studies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Dackis, CA; Gold, MS; Washton, AM	1
Feuerstein, TJ; Gleichauf, O; Jackisch, R; Landwehrmeyer, GB; Peckys, D; Scheremet, R	1
Maier, SF; McGorry, M; Schwartz, B; Sisk, D; Watkins, LR; Wiertelak, EP	1
Dun, NJ; Hwang, BH; Mizoguchi, H; Nagase, H; Narita, M; Oji, DE; Tseng, LF	1
Bocchi, C; Delsignore, R; Fontanesi, B; Gerra, G; Rustichelli, P; Timpano, M; Zaimovic, A; Zambelli, U	1
Bodnar, RJ; Christian, G; Echo, JA; Lamonte, N; Ragnauth, A; Znamensky, V	1
Ackerman, TF; Bodnar, RJ; Echo, JA; Lamonte, N	1
González-Maeso, J; Meana, JJ; Rodríguez-Puertas, R	1
Stromberg, MF	1
Gallate, JE; McGregor, IS	1
Carai, MA; Colombo, G; Gessa, GL; Serra, S; Vacca, G	1
Ameisen, O	1
Egli, M; Heilig, M	1
Bernardi, M; Caputo, F; Francini, S; Stoppo, M; Vignoli, T	1
Johnson, BA	2
Corwin, RL; Coupland, J; Ghosh, S; Rao, RE; Wojnicki, FH	1
Garbutt, JC	1
Corwin, RL; Wojnicki, FH; Wong, KJ	1
McGregor, IS; van Nieuwenhuijzen, PS	1
Choi, SM; Jung, JS; Kwon, MS; Lee, JK; Park, SH; Seo, YJ; Sim, YB; Suh, HW	1
Corwin, RL; Wojnicki, FH	1
Finn, DA; Ford, MM; Fretwell, AM; Tanchuck, MA; Yoneyama, N	1
Bidlack, JM; Dean, RL; Deaver, DR; Eyerman, D; Todtenkopf, MS; Turncliff, RZ	1
Heinz, A; Müller, CA	1
Avena, NM; Bocarsly, ME; Gold, MS; Murray, S	1
Bertrand, V; Boucard, A; Cholet, N; Chumakov, I; Cohen, D; Foucquier, J; Glibert, F; Graudens, E; Guedj, M; Hajj, R; Laffaire, J; Mandel, J; Milet, A; Nabirotchkin, S; Nave, KA; Pereira, Y; Primas, G; Sereda, MW; Vial, E	1
Al-Moussawi, M; Attarian, S; Bertrand, V; Bossi, L; Boudiaf, L; Chumakov, I; Cohen, D; Dubourg, O; Franques, J; Funalot, B; Ghorab, K; Gilbert, W; Gonnaud, PM; Guedj, M; Hajj, R; Lacour, A; Leclair-Visonneau, L; Lefebvre, MN; Lehert, P; Magot, A; Magy, L; Mandel, J; Micallef, J; Milet, A; Nabirotchkin, S; Péréon, Y; Pouget, J; Preudhomme, M; Scart-Grès, C; Stojkovic, T; Tiffreau, V; Vallat, JM	1
Lieb, M; Soyka, M	1
Hackett, D; Heal, DJ; Hutson, PH; Murray, F; Vickers, SP	1
Goh, ET; Morgan, MY	1
Lyon, J	1
Holtyn, AF; Kaminski, BJ; Weerts, EM	1
Barkley-Levenson, A; Crabbe, JC; Hack, WR; Huang, LC; Metten, P; Ozburn, AR; Schlumbohm, JP; Spence, SE	1
Boussageon, R; Duprez, R; Huneau, A; Laviolle, B; Locher, C; Naudet, F; Palpacuer, C	1
Donoghue, K	1
Ahmad, SU; Kumar, J; Mohamed, IN; Pakri Mohamed, RM	1
Diouf, M; González-Marín, MC; Jeanblanc, J; Lebourgeois, S; Naassila, M	1
Chaignot, C; Coste, J; Dray-Spira, R; Rey, G; Weill, A; Zureik, M	1
Adam, J; Cohen, D; Ewers, D; Hajj, R; Kungl, T; Mroczek, M; Nabirotchkin, S; Nave, KA; Prukop, T; Sereda, MW; Stenzel, J; Wernick, S	1
Alho, H; Castrén, S; Mäkelä, N	1
Adam, J; Barrantes-Freer, A; Bartl, M; Boussicault, L; Brureau, A; Cohen, D; Czesnik, D; Ewers, D; Hajj, R; Jäger, K; Laffaire, J; Linhoff, L; Nabirotchkin, S; Nave, KA; Primas, G; Prukop, T; Quintes, S; Rinaudo, P; Schmidt, J; Schwab, MH; Sereda, MW; Wernick, S; Winter, L; Zschüntzsch, J	1
Lesscher, HMB; Minnaard, AM; Ramakers, GMJ; Vanderschuren, LJMJ	1
Adams, D; Amato, A; Attarian, S; Brannagan, TH; Carter, G; Casanovas, C; de Visser, M; Felice, K; Magy, L; Péréon, Y; Statland, JM; Stino, A; Tard, C; Thomas, FP; Van Damme, P; Verhamme, C; Walk, D; Walter, MC; Young, P	1
Burnette, EM; Gillis, AJ; Grodin, EN; Hurley, B; Meredith, LR; Miotto, K; Nieto, SJ; Ray, LA	1
Fomin, V; Goodman, RP; Luther, J; Patel, SJ; Schaefer, E; Shay, JES; Vannier, AGL	1
Agabio, R; Minozzi, S; Rösner, S; Saulle, R	1

Reviews

14 review(s) available for naltrexone and baclofen

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
The sequential use of clonidine and naltrexone in the treatment of opiate addicts. Advances in alcohol & substance abuse, 1984,Spring, Volume: 3, Issue:3 Topics: Adult; Baclofen; Clonidine; Drug Therapy, Combination; Electric Stimulation Therapy; Endorphins; Ethanol; Female; Humans; Locus Coeruleus; Male; Methyldopa; Naloxone; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome	1984
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacology & therapeutics, 2006, Volume: 111, Issue:3 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Disease Models, Animal; Disulfiram; Fructose; Humans; Naltrexone; Neuropeptide Y; Nociceptin; Ondansetron; Opioid Peptides; Receptor, Cannabinoid, CB1; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Taurine; Topiramate	2006
Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochemical pharmacology, 2008, Jan-01, Volume: 75, Issue:1 Topics: Acamprosate; Alcoholism; Animals; Baclofen; Disulfiram; Fructose; Humans; Naltrexone; Ondansetron; Receptors, N-Methyl-D-Aspartate; Ritanserin; Selective Serotonin Reuptake Inhibitors; Taurine; Topiramate	2008
The state of pharmacotherapy for the treatment of alcohol dependence. Journal of substance abuse treatment, 2009, Volume: 36, Issue:1 Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Baclofen; Delayed-Action Preparations; Disulfiram; Fructose; Humans; Medication Adherence; Naltrexone; Taurine; Temperance; Topiramate	2009
Medication treatment of different types of alcoholism. The American journal of psychiatry, 2010, Volume: 167, Issue:6 Topics: Adult; Aged; Alcohol Deterrents; Alcoholism; Baclofen; Chronic Disease; Depressive Disorder; Female; Fructose; Humans; Hypothalamo-Hypophyseal System; Limbic System; Male; Naltrexone; Ondansetron; Pituitary-Adrenal System; Prefrontal Cortex; Receptors, Dopamine D2; Receptors, GABA; Topiramate; Young Adult	2010
[New treatment options for alcohol dependence]. MMW Fortschritte der Medizin, 2013, May-02, Volume: 155, Issue:8 Topics: Acamprosate; Alcoholism; Baclofen; Combined Modality Therapy; Ethanol; Fructose; Humans; Naltrexone; Psychotherapy; Secondary Prevention; Socioenvironmental Therapy; Substance Withdrawal Syndrome; Taurine; Topiramate	2013
Recent Developments in Pharmacotherapy of Alcoholism. Pharmacopsychiatry, 2015, Volume: 48, Issue:4-5 Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Anticonvulsants; Baclofen; Humans; Naltrexone; Narcotic Antagonists; Pharmacogenetics; Randomized Controlled Trials as Topic; Taurine; Varenicline	2015
Review article: pharmacotherapy for alcohol dependence - the why, the what and the wherefore. Alimentary pharmacology & therapeutics, 2017, Volume: 45, Issue:7 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Baclofen; Disulfiram; Drug Combinations; Fructose; Humans; Naltrexone; Polymorphism, Single Nucleotide; Pyridoxine; Pyrrolidonecarboxylic Acid; Taurine; Topiramate; Treatment Outcome	2017
Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate. Addiction (Abingdon, England), 2018, Volume: 113, Issue:2 Topics: Acamprosate; Alcoholism; Baclofen; Naltrexone; Narcotic Antagonists; Network Meta-Analysis; Topiramate; Treatment Outcome	2018
Novel Pharmacotherapeutic Approaches in Treatment of Alcohol Addiction. Current drug targets, 2018, Volume: 19, Issue:12 Topics: Alcohol Deterrents; Alcoholism; Animals; Aripiprazole; Baclofen; Cyclopentanes; Gabapentin; Humans; Naltrexone; Quetiapine Fumarate	2018
Selecting an appropriate alcohol pharmacotherapy: review of recent findings. Current opinion in psychiatry, 2019, Volume: 32, Issue:4 Topics: Acamprosate; Alcoholism; Antidepressive Agents; Baclofen; Cholinergic Agonists; Disulfiram; Gabapentin; Humans; Naltrexone; Ondansetron; Randomized Controlled Trials as Topic; Treatment Outcome	2019
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder. Drugs, 2022, Volume: 82, Issue:3 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Baclofen; Disulfiram; Humans; Naltrexone; Topiramate	2022
Baclofen for alcohol use disorder. The Cochrane database of systematic reviews, 2023, 01-13, Volume: 1 Topics: Acamprosate; Adult; Alcohol Drinking; Alcoholism; Baclofen; Chronic Disease; Female; Humans; Male; Middle Aged; Naltrexone	2023

Trials

3 trial(s) available for naltrexone and baclofen

Article	Year
Rapid opiate detoxication in outpatient treatment: relationship with naltrexone compliance. Journal of substance abuse treatment, 2000, Volume: 18, Issue:2 Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Anti-Inflammatory Agents, Non-Steroidal; Baclofen; Clonidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; GABA Agents; Heroin Dependence; Humans; Inactivation, Metabolic; Ketoprofen; Male; Methadone; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Oxazepam; Patient Compliance; Substance Withdrawal Syndrome; Treatment Outcome	2000
An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A. Orphanet journal of rare diseases, 2014, Dec-18, Volume: 9 Topics: Adult; Baclofen; Charcot-Marie-Tooth Disease; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Sorbitol	2014
A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot-Marie-Tooth type 1A. Orphanet journal of rare diseases, 2021, 10-16, Volume: 16, Issue:1 Topics: Baclofen; Charcot-Marie-Tooth Disease; Double-Blind Method; Humans; Naltrexone; Sorbitol	2021

Other Studies

36 other study(ies) available for naltrexone and baclofen

Article	Year
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. Journal of medicinal chemistry, 2008, Oct-09, Volume: 51, Issue:19 Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship	2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Opioid receptor-mediated control of acetylcholine release in human neocortex tissue. Naunyn-Schmiedeberg's archives of pharmacology, 1996, Volume: 354, Issue:5 Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Acetylcholine; Adolescent; Adult; Aged; Analgesics; Analysis of Variance; Baclofen; Cerebral Cortex; Dose-Response Relationship, Drug; Electric Stimulation; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalin, D-Penicillamine (2,5)-; Enkephalins; Female; GABA Agonists; Humans; Male; Middle Aged; Muscimol; Naloxone; Naltrexone; Narcotic Antagonists; Pyrrolidines; Receptors, Opioid, delta; Tetrodotoxin	1996
Reversal of spinal cord non-opiate analgesia by conditioned anti-analgesia in the rat. Pain, 1997, Volume: 71, Issue:3 Topics: Analgesia, Epidural; Analgesics, Non-Narcotic; Analysis of Variance; Animals; Baclofen; Biguanides; Conditioning, Classical; Drug Evaluation, Preclinical; GABA Agonists; Isonicotinic Acids; Male; Naltrexone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley; Serotonin Receptor Agonists; Spinal Cord	1997
Identification of the G-protein-coupled ORL1 receptor in the mouse spinal cord by [35S]-GTPgammaS binding and immunohistochemistry. British journal of pharmacology, 1999, Volume: 128, Issue:6 Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Atropine; Autoradiography; Baclofen; Binding, Competitive; Dose-Response Relationship, Drug; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalin, D-Penicillamine (2,5)-; GTP-Binding Proteins; Guanosine 5'-O-(3-Thiotriphosphate); Guanosine Diphosphate; Haloperidol; Immunohistochemistry; In Vitro Techniques; Male; Membranes; Mice; Mice, Inbred ICR; Naltrexone; Narcotic Antagonists; Nociceptin; Nociceptin Receptor; Opioid Peptides; Peptide Fragments; Propranolol; Receptors, Opioid; Somatostatin; Spinal Cord; Sulfur Radioisotopes; Yohimbine	1999
gamma-Aminobutyric acid receptor subtype antagonists differentially alter opioid-induced feeding in the shell region of the nucleus accumbens in rats. Brain research, 2001, Jul-06, Volume: 906, Issue:1-2 Topics: Animals; Baclofen; Bicuculline; Eating; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; GABA Agonists; GABA Antagonists; GABA-A Receptor Antagonists; GABA-B Receptor Antagonists; gamma-Aminobutyric Acid; Male; Naltrexone; Narcotic Antagonists; Narcotics; Neurons; Nucleus Accumbens; Rats; Rats, Sprague-Dawley; Receptors, GABA; Receptors, GABA-A; Receptors, GABA-B; Receptors, Opioid	2001
Alterations in food intake elicited by GABA and opioid agonists and antagonists administered into the ventral tegmental area region of rats. Physiology & behavior, 2002, May-01, Volume: 76, Issue:1 Topics: Administration, Oral; Analgesics, Opioid; Animals; Baclofen; Eating; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Food Preferences; GABA Agonists; GABA Antagonists; GABA-A Receptor Agonists; GABA-A Receptor Antagonists; GABA-B Receptor Agonists; GABA-B Receptor Antagonists; Male; Microinjections; Muscimol; Naltrexone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Opioid; Receptors, Opioid, mu; Ventral Tegmental Area	2002
Quantitative stoichiometry of G-proteins activated by mu-opioid receptors in postmortem human brain. European journal of pharmacology, 2002, Sep-27, Volume: 452, Issue:1 Topics: Alkylation; Analgesics, Opioid; Baclofen; Binding, Competitive; Brain Chemistry; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enzyme Inhibitors; Ethylmaleimide; GABA Agonists; GTP-Binding Protein Regulators; GTP-Binding Proteins; Humans; In Vitro Techniques; Kinetics; Membranes; Naloxone; Naltrexone; Narcotic Antagonists; Receptors, Opioid, mu; Signal Transduction	2002
The effect of baclofen alone and in combination with naltrexone on ethanol consumption in the rat. Pharmacology, biochemistry, and behavior, 2004, Volume: 78, Issue:4 Topics: Alcohol Drinking; Animals; Baclofen; Dose-Response Relationship, Drug; GABA Agonists; Male; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar	2004
Rats on the grog: novel pharmacotherapies for alcohol craving. Addictive behaviors, 2004, Volume: 29, Issue:7 Topics: Alcoholism; Animals; Baclofen; Beer; Behavior, Addictive; Cannabinoid Receptor Antagonists; Corticotropin-Releasing Hormone; Humans; Models, Animal; Naltrexone; Narcotic Antagonists; Neuropeptide Y; Piperidines; Pyrazoles; Rats; Receptors, Corticotropin-Releasing Hormone; Receptors, GABA-B; Research Design; Rimonabant	2004
Effect of the combination of naltrexone and baclofen, on acquisition of alcohol drinking behavior in alcohol-preferring rats. Drug and alcohol dependence, 2005, Jan-07, Volume: 77, Issue:1 Topics: Alcohol Drinking; Animals; Baclofen; Drug Therapy, Combination; Male; Naltrexone; Rats	2005
Naltrexone treatment for alcohol dependency. JAMA, 2005, Aug-24, Volume: 294, Issue:8 Topics: Administration, Oral; Alcoholism; Animals; Baclofen; Ethanol; GABA Agonists; Humans; Naltrexone; Narcotic Antagonists	2005
GABAergic medications for treating alcohol dependence. Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:5 Topics: Alcoholism; Baclofen; Drug Therapy, Combination; GABA Agonists; gamma-Aminobutyric Acid; Humans; Hydroxybutyrates; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Receptors, GABA-B; Substance Withdrawal Syndrome; Temperance	2007
Baclofen, raclopride, and naltrexone differentially reduce solid fat emulsion intake under limited access conditions. Pharmacology, biochemistry, and behavior, 2008, Volume: 89, Issue:4 Topics: Animals; Baclofen; Bulimia; Dietary Fats; Dopamine Antagonists; Eating; Emulsions; Feeding Behavior; GABA Agonists; Male; Naltrexone; Narcotic Antagonists; Raclopride; Rats; Rats, Sprague-Dawley	2008
Baclofen, raclopride, and naltrexone differentially affect intake of fat/sucrose mixtures under limited access conditions. Pharmacology, biochemistry, and behavior, 2009, Volume: 92, Issue:3 Topics: Animals; Baclofen; Dietary Fats; Dietary Sucrose; Dopamine Antagonists; Feeding Behavior; GABA Agonists; Male; Naltrexone; Raclopride; Rats; Rats, Sprague-Dawley	2009
Sedative and hypothermic effects of gamma-hydroxybutyrate (GHB) in rats alone and in combination with other drugs: assessment using biotelemetry. Drug and alcohol dependence, 2009, Aug-01, Volume: 103, Issue:3 Topics: Animals; Baclofen; Benzazepines; Dose-Response Relationship, Drug; Drug Interactions; Drug Tolerance; Flumazenil; Hypothermia; Illicit Drugs; Male; Methamphetamine; Morpholines; Motor Activity; N-Methyl-3,4-methylenedioxyamphetamine; Naltrexone; Rats; Rats, Wistar; Ritanserin; Sodium Oxybate; Telemetry	2009
Possible involvement of the hypothalamic pro-opiomelanocortin gene and beta-endorphin expression on acute morphine withdrawal development. Brain research bulletin, 2009, Dec-16, Volume: 80, Issue:6 Topics: Animals; Arcuate Nucleus of Hypothalamus; Baclofen; beta-Endorphin; Dose-Response Relationship, Drug; GABA Agonists; Gene Expression; Hypothalamus; Male; Mice; Mice, Inbred ICR; Morphine; Muscimol; Naltrexone; Narcotic Antagonists; Narcotics; Pro-Opiomelanocortin; Substance Withdrawal Syndrome	2009
Baclofen, raclopride, and naltrexone differentially affect intake of fat and sucrose under limited access conditions. Behavioural pharmacology, 2009, Volume: 20, Issue:5-6 Topics: Analysis of Variance; Animals; Baclofen; Benzazepines; Conditioning, Operant; Dopamine Antagonists; Dose-Response Relationship, Drug; Eating; Fats; Feeding Behavior; Food Preferences; GABA Agonists; Male; Naltrexone; Narcotic Antagonists; Raclopride; Rats; Rats, Sprague-Dawley; Reinforcement Schedule; Sucrose; Sweetening Agents	2009
Alcohol dependence: after the withdrawal phase. Long-term abstinence: better health and psychosocial status. Psychosocial support for a chronic disorder. Some drugs are useful adjuncts to medical support. Prescrire international, 2009, Volume: 18, Issue:103 Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Alcoholics; Alcoholism; Anticonvulsants; Baclofen; Clinical Trials as Topic; Combined Modality Therapy; Disulfiram; France; Fructose; Health Status; Humans; Naltrexone; Psychotherapy; Randomized Controlled Trials as Topic; Secondary Prevention; Self-Help Groups; Social Support; Taurine; Temperance; Topiramate; Treatment Outcome	2009
Assessment of GABA-B, metabotropic glutamate, and opioid receptor involvement in an animal model of binge drinking. Alcohol (Fayetteville, N.Y.), 2011, Volume: 45, Issue:1 Topics: Alcohol Drinking; Animals; Baclofen; Disease Models, Animal; Ethanol; Excitatory Amino Acid Antagonists; GABA-B Receptor Agonists; Male; Mice; Mice, Inbred C57BL; Naltrexone; Narcotic Antagonists; Pyridines; Receptors, GABA-B; Receptors, Metabotropic Glutamate; Receptors, Opioid; Self Administration; Sucrose	2011
Effects of oral loperamide on efficacy of naltrexone, baclofen and AM-251 in blocking ethanol self-administration in rats. Pharmacology, biochemistry, and behavior, 2012, Volume: 100, Issue:3 Topics: Administration, Oral; Alcohol Deterrents; Alcohol Drinking; Animals; Animals, Outbred Strains; Baclofen; Behavior, Animal; Drug Synergism; Drug Therapy, Combination; GABA-B Receptor Agonists; Loperamide; Male; Naltrexone; Narcotic Antagonists; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Receptors, Opioid, kappa; Receptors, Opioid, mu	2012
KASL clinical practice guidelines: management of alcoholic liver disease. Clinical and molecular hepatology, 2013, Volume: 19, Issue:3 Topics: Alcohol Abstinence; Alcohol Drinking; Alcohol-Related Disorders; Baclofen; Disulfiram; Fatty Liver, Alcoholic; Hepatitis, Alcoholic; Humans; Liver Cirrhosis; Liver Diseases, Alcoholic; Naltrexone; Prevalence; Prognosis; Risk Factors; Severity of Illness Index; Surveys and Questionnaires	2013
Effects of baclofen and naltrexone, alone and in combination, on the consumption of palatable food in male rats. Experimental and clinical psychopharmacology, 2014, Volume: 22, Issue:5 Topics: Analysis of Variance; Animals; Baclofen; Dose-Response Relationship, Drug; Drug Combinations; Eating; Feeding Behavior; Food Preferences; GABA-B Receptor Agonists; Male; Naltrexone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley	2014
Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy. Orphanet journal of rare diseases, 2014, Dec-10, Volume: 9 Topics: Animals; Axons; Baclofen; Charcot-Marie-Tooth Disease; Coculture Techniques; Disease Models, Animal; Down-Regulation; Drug Repositioning; Drug Therapy, Combination; Female; Gene Expression Regulation; Male; Mice; Myelin Proteins; Naltrexone; Nerve Fibers, Myelinated; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Sciatic Neuropathy; Sorbitol	2014
Effects of lisdexamfetamine in a rat model of binge-eating. Journal of psychopharmacology (Oxford, England), 2015, Volume: 29, Issue:12 Topics: Animals; Baclofen; Behavior, Animal; Benzazepines; Benzodiazepines; Body Weight; Bulimia; Disease Models, Animal; Eating; Feeding Behavior; Female; Idazoxan; Lisdexamfetamine Dimesylate; Naltrexone; Olanzapine; Prazosin; Prodrugs; Raclopride; Rats; Rats, Wistar; Rolipram	2015
More Treatments on Deck for Alcohol Use Disorder. JAMA, 2017, Jun-13, Volume: 317, Issue:22 Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Amines; Baclofen; Cyclohexanecarboxylic Acids; Cytidine Diphosphate Choline; Disulfiram; Drug Repositioning; Fructose; Gabapentin; gamma-Aminobutyric Acid; Humans; Mifepristone; Naltrexone; National Institute on Alcohol Abuse and Alcoholism (U.S.); Off-Label Use; Patient Acceptance of Health Care; Taurine; Topiramate; United States; Varenicline	2017
Baclofen and naltrexone effects on alcohol self-administration: Comparison of treatment initiated during abstinence or ongoing alcohol access in baboons. Drug and alcohol dependence, 2017, 10-01, Volume: 179 Topics: Alcohol Abstinence; Alcohol Drinking; Alcoholism; Animals; Baclofen; Disease Models, Animal; GABA-B Receptor Agonists; Naltrexone; Papio; Reinforcement, Psychology; Self Administration	2017
High Drinking in the Dark (HDID) mice are sensitive to the effects of some clinically relevant drugs to reduce binge-like drinking. Pharmacology, biochemistry, and behavior, 2017, Volume: 160 Topics: Acamprosate; Animals; Baclofen; Binge Drinking; Darkness; Disease Models, Animal; Ethanol; Female; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Naltrexone; Taurine	2017
Commentary on Palpacuer et al. (2018): Do small effects on total alcohol consumption translate into clinical practice? Addiction (Abingdon, England), 2018, Volume: 113, Issue:2 Topics: Acamprosate; Alcohol Drinking; Alcoholism; Baclofen; Humans; Naltrexone; Narcotic Antagonists; Network Meta-Analysis; Topiramate	2018
Evaluation of alcohol use disorders pharmacotherapies in a new preclinical model of binge drinking. Neuropharmacology, 2018, 09-15, Volume: 140 Topics: Acamprosate; Animals; Baclofen; Binge Drinking; Conditioning, Operant; Disease Models, Animal; Dose-Response Relationship, Drug; Ethanol; Extinction, Psychological; Hydroxybutyrates; Male; Motivation; Naltrexone; Rats; Self Administration	2018
Risk of hospitalisation and death related to baclofen for alcohol use disorders: Comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France. Pharmacoepidemiology and drug safety, 2018, Volume: 27, Issue:11 Topics: Acamprosate; Administrative Claims, Healthcare; Adult; Aged; Alcohol Deterrents; Alcoholism; Baclofen; Databases, Factual; Dose-Response Relationship, Drug; Female; Follow-Up Studies; France; Hospitalization; Humans; Male; Middle Aged; Naltrexone; Off-Label Use; Risk Assessment; Socioeconomic Factors	2018
Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A). PloS one, 2019, Volume: 14, Issue:1 Topics: Animals; Axons; Baclofen; Charcot-Marie-Tooth Disease; Demyelinating Diseases; Disease Models, Animal; Drug Combinations; Male; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Muscle Weakness; Myelin Proteins; Naltrexone; Neural Conduction; Phosphatidylinositol 3-Kinases; Proof of Concept Study; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Schwann Cells; Signal Transduction; Sorbitol	2019
Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot-Marie-Tooth disease type 1A (CMT1A) rats. Journal of neuroscience research, 2020, Volume: 98, Issue:10 Topics: Animals; Baclofen; Charcot-Marie-Tooth Disease; Coculture Techniques; Demyelinating Diseases; Drug Synergism; Drug Therapy, Combination; Female; Male; Myelin Proteins; Naltrexone; Neural Conduction; Neuromuscular Junction; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Sorbitol	2020
Baclofen and naltrexone, but not N-acetylcysteine, affect voluntary alcohol drinking in rats regardless of individual levels of alcohol intake. Behavioural pharmacology, 2021, 04-01, Volume: 32, Issue:2&3 Topics: Acetylcysteine; Alcohol Drinking; Animals; Baclofen; Ethanol; GABA-B Receptor Agonists; Male; Naltrexone; Narcotic Antagonists; Rats	2021
Incidence and Progression of Alcohol-Associated Liver Disease After Medical Therapy for Alcohol Use Disorder. JAMA network open, 2022, 05-02, Volume: 5, Issue:5 Topics: Alcoholism; Baclofen; Female; Gabapentin; Humans; Incidence; Liver Cirrhosis; Male; Middle Aged; Naltrexone; Retrospective Studies; Topiramate	2022